

# U.S. Liquid Biopsy Market to Surpass \$12 Billion by 2032, Driven by a 13.68% CAGR | Astute Analytica

CHICAGO, CA, UNITED STATES, September 27, 2024

/EINPresswire.com/ -- [www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market](https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market)  
The U.S. liquid biopsy market is projected to reach \$12 billion by 2032, driven by a 13.68% CAGR. This growth is fueled by the increasing prevalence of cancer and advancements in precision medicine. The market is expected to grow from \$3.79 billion in 2023 to \$12 billion by 2032. The report provides a comprehensive analysis of the market, including key players, market trends, and future outlook.

**Key Market Insights:** The U.S. liquid biopsy market is experiencing rapid growth, driven by the increasing prevalence of cancer and advancements in precision medicine.

Liquid biopsy, a non-invasive diagnostic technique that detects cancer-related genetic mutations in blood, has emerged as a powerful tool in oncology. The increasing prevalence of cancer, coupled with advancements in precision medicine, is propelling the adoption of liquid biopsies in the U.S.

**Request a Sample Report:** For more information, visit <https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market>

<https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market>

**Market Outlook:** The U.S. liquid biopsy market is expected to continue its rapid growth, driven by the increasing prevalence of cancer and advancements in precision medicine.

**Key Market Drivers:** The escalating rates of cancer diagnosis in the U.S. are fueling demand for early detection methods. Liquid biopsy's ability to detect cancer at an early stage offers significant clinical benefits.

**Continuous Innovation:** Continuous innovation in liquid biopsy technologies, such as next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis, is enhancing the accuracy and reliability of these tests.

**Future Outlook:** With a growing emphasis on tailored treatment strategies, liquid biopsy is becoming a cornerstone of precision medicine. It allows oncologists to monitor treatment response and make informed decisions, leading to better patient outcomes.



Market Overview: The U.S. liquid biopsy market was valued at \$3,786.2 million in 2023. However, by 2032, it is expected to surpass a market valuation of \$12,004.9 million, representing a significant increase over the forecast period.

Increased Adoption in Clinical Settings: Liquid biopsy is gaining traction in routine clinical practice, as it provides a minimally invasive alternative to traditional tissue biopsies.

Expansion of Companion Diagnostics: The FDA's approval of liquid biopsy tests as companion diagnostics is enabling pharmaceutical companies to develop targeted therapies in conjunction with diagnostic tools.

Rising Demand for Non-Invasive Testing: The preference for less invasive diagnostic procedures is bolstering the liquid biopsy market, particularly in cases where tissue samples are difficult to obtain.

Challenges and Opportunities: Stringent regulatory requirements can slow the approval process for new liquid biopsy tests. However, ongoing collaborations between diagnostic companies and regulatory bodies are expected to mitigate these challenges.

High Cost of Liquid Biopsy Tests: The high cost of liquid biopsy tests may limit access to these diagnostics, particularly in underinsured populations. Nevertheless, as the technology matures and becomes more widely available, costs are expected to decrease.

Future Outlook: Although the primary focus of liquid biopsy is oncology, there is growing interest in its potential applications beyond cancer detection. Researchers are exploring its use in detecting other conditions, such as cardiovascular diseases and neurodegenerative disorders.

Conclusion: This expanding scope of liquid biopsy applications presents lucrative opportunities for market players, who can leverage their expertise to diversify into new areas of healthcare diagnostics.

For more information, visit: <https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market>

000000000000 0000000000: 000 00000000 00000000 000 0000000

00000000 0000000000 0000000000 000 00000000 000000000000 00 000 0.0. 00000000 00000000  
00000000. 000000 000 00000000 000000000:

Biocept, Inc.  
Illumina, Inc.  
Myriad Genetics, Inc.  
QIAGEN  
Thermo Fisher Scientific, Inc.  
Guardant Health  
F. Hoffmann-La Roche Ltd  
ANGLE plc  
BIODESIX  
NeoGenomics Laboratories, Inc.  
Other major players

0000000 000000000000000 0000000000:

00 000000000000  
Multi Gene Parallel Analysis (NGS)  
Single Gene Analysis (PCR Microarrays)

00 000000000  
Blood Sample Based  
Others

00 00000000000  
Circulating Nucleic Acids  
CTC  
Exosomes/Microvesicles  
Circulating Proteins

000000000000: 0 00000000000 00000000 000 000 0.0. 00000000 00000000 00000000  
With a projected CAGR of 13.68% from 2024 to 2032, the U.S. liquid biopsy market is on a path of robust growth. The combination of technological advancements, increased adoption in clinical practice, and the rising demand for personalized medicine will continue to drive the market forward. By 2032, liquid biopsy is expected to become an indispensable tool in the early detection and management of cancer, solidifying its role in the future of healthcare.

00000000 00000 00000 00 000 00000 00000000: -<https://www.astuteanalytica.com/request-sample/united-states-liquid-biopsy-market>

□□□□□ □□□□□□ □□□□□□□□□□:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Mirza Aamir Beg  
Astute Analytica  
+91 99108 20439  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/747010951>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.